NAB2 and neoplasm: In this study, we showed that RNA-targeting technologies (antisense oligonucleotides and CRISPR/CasRx) can be used to specifically suppress the expressions of NAB2–STAT6 fusion transcripts, but not wild type STAT6, and reduce cell proliferation and tumor growth.